Equillium, Inc. (EQ)
| Market Cap | 129.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.40M |
| Shares Out | 63.23M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,556 |
| Open | 2.060 |
| Previous Close | 2.040 |
| Day's Range | 2.010 - 2.220 |
| 52-Week Range | 0.270 - 2.700 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+291.2%) |
| Earnings Date | May 25, 2026 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 291.20% from the latest price.
News
Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter
Equillium to Participate in the 38th Annual Roth Conference
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today ann...
Equillium Announces $35 Million Financing with RA Capital Management
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA,...
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today anno...
Equillium Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
EQ504, a selective AhR modulator with colon-specific delivery, targets key disease mechanisms in ulcerative colitis and is supported by strong preclinical and translational data. Phase I studies are set to begin mid-year in Australia, with a robust financial runway and plans for broader indication expansion.
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics ...
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR...
Equillium Transcript: KOL Event
The event highlighted the scientific and clinical rationale for AHR modulation in ulcerative colitis, emphasizing EQ504’s dual action on immune regulation and tissue repair. Experts discussed strong preclinical and clinical data, strategic positioning for combination therapy, and plans for targeted colonic delivery to maximize efficacy and safety.
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis Virtual webinar to feat...
Equillium Announces Leadership and Corporate Updates
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neur...
Equillium Transcript: Cantor Global Healthcare Conference 2025
EQ504, a novel AhR modulator targeting ulcerative colitis, is advancing toward Phase I trials after a $50 million financing. Preclinical data show strong mucosal healing and cytokine induction, with clinical studies set to begin mid-2025.
Equillium to Participate in the Cantor Global Healthcare Conference 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inf...
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced ...
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
Equillium Announces Feedback from the U.S. Food and Drug Administration
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe a...
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD)...
Equillium Transcript: Study Result
The phase III EQUATOR study in first-line acute GVHD showed itolizumab did not meet the primary endpoint at day 29 but demonstrated significant long-term benefits, including higher complete response rates at day 99, longer duration of response, and improved failure-free survival, with a favorable safety profile. Regulatory discussions for accelerated approval are underway.
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...